A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
Completed
Eisai Inc.
2006-04-01
This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where
the principal investigator will be a pharmacist.
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
Completed
Eisai Inc.
Phase 2
2005-08-01
The primary objective of this study is to collect safety information on rabeprazole 10 mg and
20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16
years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement
of the symptoms of GERD and to explore the relationship of symptom relief to dose received,
based on symptom frequency and severity, antacid use, and quality of life (QOL) measures.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
